Hydroxyurea has many characteristics of an ideal drug for sickle cell anemia (SCA) and
provides therapeutic benefit through multiple mechanisms of action. Over the past 25 years …

Background Sickle cell disease (SCD) is one of the most common inherited diseases
worldwide. It is associated with lifelong morbidity and a reduced life expectancy …

Although sickle cell disease (SCD) is marked by high utilization of medical resources, the full
cost of care for patients with SCD, including care not directly related to SCD, is unknown …

An 18-year-old woman with sickle cell anemia presents with recurrent painful crises, and
treatment with hydroxyurea is recommended. Hydroxyurea causes a shift toward the …

Background: Hydroxyurea is the only approved drug for treatment of sickle cell disease.
Objective: To synthesize the published literature on the efficacy, effectiveness, and toxicity of …

Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by microvascular
vaso-occlusion with erythrocytes containing polymerized sickle (S) hemoglobin, erythrocyte …

While laboratory and clinical benefits of hydroxyurea for patients with sickle cell disease
(SCD) are well‐established, few data describe the extent and implications of non …

Sickle cell disease (SCD) is an inherited disorder of haemoglobin synthesis that is
associated with significant morbidity and mortality due to sequelae of episodic vaso …

Review Page 1 Review THE ROLE OF HYDROXYUREA IN SICKLE CELL DISEASE
Although the molecular basis for the sickling disorders was identified more than 50 years …

Background Sickle cell disease (SCD) is an inherited blood disorder causing acute
complications and chronic progressive end organ damage. SCD is associated with …